Studies have shown that refractory metastatic melanoma patients that receive cell infusion with autologous tumor-reactive, rapidly expanded TIL cultures, and high-dose Interleukin-2 (IL-2) therapy have improved outcomes. This evidence concerns the gene IL2 and neoplasm.